Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable
As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.
Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.
Featuring key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this is your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.
Announcing the Crews & Deshaies Award for the Induced Proximity Innovator of the Year
Get ready for the best TPD & Induced Proximity Summit to date—featuring the field’s original pioneers, Craig Crews and Ray Deshaies. Join us to hear their insights on where induced proximity is headed, the latest developments from the Crews lab, and celebrate the launch of the first-ever “Crews & Deshaies Award for the Induced Proximity Innovator of the Year” at the Annual TPD & Induced Proximity Awards. With Arvinas’s recent NDA submission marking what could be the first FDA-approved PROTAC, alongside exciting clinical advances from other leading players, 2025 is shaping up to be a landmark year for the field. There’s no better time to learn from the trailblazers who started it all.
"The concept of modulating protein function through induced proximity has the potential to utterly transform what is possible to achieve with pharmacotherapy. The field is approaching the crucial milestone of regulatory approval for a prospectively-developed degrader molecule, but this is only ‘the end of the beginning’. New ideas will propel the field forward in new directions, and we seek to recognize the leading innovators with this award." — Ray Deshaies
“It’s been exciting to watch the Induced Proximity field go from a Chemical Biology concept to the cusp of possible FDA approval. Given the current excitement and momentum in the field, it is a good time for the community to recognize those innovators who are pushing the boundaries of ‘what is possible’.” — Craig Crews
Attending Companies Include














